A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Trial Details

NCT ID
NCT07644559
Phase
PHASE2
Sponsor
Verastem, Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • VS-7375
  • cetuximab
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Coral Springs, Florida, United States|26.27119,-80.2706
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • Histologic or cytologic confirmed PDAC
  • Measurable disease per RECIST 1.1
  • Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
  • ECOG PS=0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →